29Mar 2024
Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

A comprehensive meta-analysis examined the efficacy of P2Y12 inhibitor monotherapy following a brief dual antiplatelet therapy (DAPT) among patients undergoing percutaneous coronary intervention (PCI). Analyzing 6 trials involving 25,960 patients, the study compared ticagrelor and clopidogrel monotherapy to standard DAPT. Ticagrelor monotherapy was found noninferior to DAPT for major outcomes, including all-cause death, MI, or stroke, with reduced major bleeding and net adverse clinical events (NACE). However, clopidogrel monotherapy, though reducing bleeding, did not meet noninferiority criteria due to higher noncardiovascular death risk. The findings suggest ticagrelor monotherapy's superiority in safety and efficacy over clopidogrel.

  • #cardiology

Like

Save

Share